Neurodegenerative Disease Treatment Market Report by Indication, Drug Type, Route of Administration, Distribution Channel, and Region 2024-2032
세계 신경퇴행성 질환 치료 시장 규모는 2023년 747억 달러에 달했습니다. 향후 IMARC Group은 2032년까지 시장 규모가 1,146억 달러에 달하고, 2024-2032년간 4.7%의 연평균 성장률(CAGR)을 나타낼 것으로 예측했습니다.
신경퇴행성 질환은 중추신경계(CNS) 또는 말초신경계(PNS) 뉴런의 구조와 기능이 점진적으로 변성되는 뇌질환군을 말합니다. 현재 신체적 또는 정신적 증상을 완화하고 환자의 삶의 질을 개선하기 위해 여러 가지 약물을 사용할 수 있습니다. 또한 연구자들은 신경퇴행성 질환을 조기에 발견하고 진단하며 진행을 예방하기 위한 분자진단법, 특히 바이오마커와 영상 분광법을 개발하는 데 주력하고 있습니다.
과도한 알코올 섭취로 인한 종양과 뇌졸중의 유병률 증가는 노인 인구 증가와 함께 신경퇴행성 질환의 발병 위험을 증가시키는 주요 요인 중 하나입니다. 이는 알츠하이머병, 파킨슨병, 헌팅턴병, 근위축성 측색경화증과 같은 신경퇴행성 질환의 조기 진단을 위한 분자진단 기술의 필요성을 더욱 높이고 있습니다. 이와는 별도로, 연구자들은 이러한 질환의 분류를 효과적으로 이해하기 위해 신경병리학적인 방법과 분자생물학적 방법을 결합하고 있습니다. 또한, 다양한 유형의 신경퇴행성 질환에 대한 최소침습(MI) 스크리닝 시험의 개발도 진행되고 있습니다. 또한, 신경퇴행성 질환의 위험 요인에 대한 인식을 높이기 위해 비정부기구(NGO)와 함께 많은 국가의 정부 기관이 다양한 건강 교육 캠페인을 지원하고 있습니다. 인프라 개선으로 인한 의료 시설에 대한 접근성 증가와 가처분 소득 증가와 같은 다른 요인들도 향후 몇 년동안 시장 성장을 가속할 것으로 예상됩니다.
본 보고서에서 다룬 주요 질문들
- 세계 신경퇴행성 질환 치료 시장은 지금까지 어떻게 성장해 왔을까?
- 코로나19는 세계 신경퇴행성 질환 치료 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은?
- 적응증별 시장 현황은?
- 약제 유형별 시장 현황은?
- 투여경로별 시장 현황은?
- 판매 채널별 시장 현황은?
- 산업 가치사슬의 다양한 단계는?
- 업계의 주요 촉진요인과 과제는?
- 세계 신경퇴행성 질환 치료 시장 구조와 주요 진출 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 신경퇴행성 질환 치료 시장
- 시장 개요
- 시장 분석
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 적응증별
- 다발성 경화증
- 파킨슨병
- 알츠하이머병
- 척수성 근위축증(SMA)
- 헌팅턴병
- 기타
제7장 시장 분석 : 약제 유형별
- N-methyl-D-aspartate Receptor Antagonists
- Selective Serotonin Reuptake Inhibitors
- Dopamine Inhibitors
- 기타
제8장 시장 분석 : 투여 경로별
제9장 시장 분석 : 유통 채널별
제10장 시장 분석 : 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter의 Five Forces 분석
- 개요
- 바이어의 교섭력
- 공급 기업의 교섭력
- 경쟁 정도
- 신규 진출업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 개요
- Biogen
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche AG
- GlaxoSmithKline Plc
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A
- Teva Pharmaceutical Industries Ltd.
- UCB S.A
LSH
The global neurodegenerative disease treatment market size reached US$ 74.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 114.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.
Neurodegenerative diseases refer to a group of brain disorders that lead to progressive degeneration of the structure and function of neurons in the central nervous system (CNS) or peripheral nervous system (PNS). Presently, several medications are available to reduce physical or mental symptoms and improve the quality of patients' life. Moreover, researchers are focusing on developing molecular diagnostics, especially biomarkers and imaging spectroscopy, to detect and diagnose neurodegenerative diseases at an early stage and prevent their progression.
The growing prevalence of tumors and stroke on account of excessive alcohol consumption, in confluence with the rising geriatric population, represents one of the major factors increasing the risk of developing neurodegenerative diseases. This is further escalating the need for molecular diagnostic techniques for early diagnosis of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Apart from this, researchers are combining neuropathological methods with molecular biology techniques to understand the classification of these diseases effectively. They are also developing minimally invasive (MI) screening tests for different types of neurodegenerative diseases. Furthermore, governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of neurodegenerative diseases. Other factors, such as increasing access to healthcare facilities on account of improving infrastructure and inflating disposable incomes, are anticipated to drive the growth of the market in the coming years.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global neurodegenerative disease treatment market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, drug type, route of administration and distribution channel.
Breakup by Indication:
Multiple Sclerosis
Parkinson's Disease
Alzheimer's Disease
Spinal Muscular Atrophy (SMA)
Huntington's Disease
Others
Breakup by Drug Type:
N-methyl-D-aspartate Receptor Antagonists
Selective Serotonin Reuptake Inhibitors
Dopamine Inhibitors
Others
Breakup by Route of Administration:
Oral
Injectable
Others
Breakup by Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biogen, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd. and UCB S.A.
Key Questions Answered in This Report:
- How has the global neurodegenerative disease treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global neurodegenerative disease treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global neurodegenerative disease treatment market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Neurodegenerative Disease Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Indication
- 6.1 Multiple Sclerosis
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Parkinson's Disease
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Alzheimer's Disease
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Spinal Muscular Atrophy (SMA)
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 Huntington's Disease
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
- 6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast
7 Market Breakup by Drug Type
- 7.1 N-methyl-D-aspartate Receptor Antagonists
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Selective Serotonin Reuptake Inhibitors
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Dopamine Inhibitors
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Route of Administration
- 8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Others
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
9 Market Breakup by Distribution Channel
- 9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Biogen
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.1.4 SWOT Analysis
- 15.3.2 Boehringer Ingelheim International GmbH
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 F. Hoffmann-La Roche AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.4 GlaxoSmithKline Plc
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 SWOT Analysis
- 15.3.5 Merck & Co. Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Pfizer Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Sanofi S.A
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Teva Pharmaceutical Industries Ltd.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 UCB S.A
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
